Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lineage Cell Therapeutics, Inc. (LCTX) vs Cartesian Therapeutics, Inc. (RNAC)

Lineage Cell Therapeutics, Inc. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and Cartesian Therapeutics, Inc. are of similar size ($239.7M and $230.6M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −94.8%. Cartesian Therapeutics, Inc. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 17 metrics below, Cartesian Therapeutics, Inc. leads on 10 and Lineage Cell Therapeutics, Inc. on 7.

Valuation

Metric LCTX RNAC Biotechnology median
P/E n/m n/m 7.88
P/S 19.64 123.01 11.47
P/B 4.30 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 15.76 75.40 10.73
Earnings yield (13.96%) (80.03%) (28.84%)
Free cash flow yield (9.49%) (36.00%) (23.03%)

Profitability

Metric LCTX RNAC Biotechnology median
Gross margin 99.46% 100.00% 65.16%
Operating margin (205.23%) 0.00% 0.00%
Net margin (246.58%) 0.00% 0.00%
Free cash flow margin (186.43%) 0.00% 0.00%
Return on equity (60.35%) 236.88% (57.72%)
Return on assets (32.75%) (42.77%) (49.22%)
Return on invested capital (186.79%) 0.00% 0.00%

Growth

Metric LCTX RNAC Biotechnology median
Revenue growth (TTM) 19.87% (94.81%) 5.64%
EPS growth (last fiscal year) (211.11%) (11.80%) —
Revenue growth, 5-year CAGR 51.46% (29.96%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LCTX RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 6.61 7.48 4.73
Net debt to EBITDA 2.64 0.89 0.96

Dividend

Metric LCTX RNAC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric LCTX RNAC Biotechnology median
Market cap 239.71m 230.55m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack